A Mulit-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients with Haemophilia A

Grants and Contracts Details

StatusFinished
Effective start/end date11/15/101/31/13

Funding

  • Novo Nordisk Pharmaceuticals Inc: $17,451.00